Panaji Journal

Severe Hypertriglyceridemia Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Severe Hypertriglyceridemia Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 26
06:13 2023
Severe Hypertriglyceridemia Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Severe Hypertriglyceridemia Pipeline Insights
DelveInsight’s, “Severe Hypertriglyceridemia – Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

United States, Nevada, Las Vegas, DelveInsight’s Severe Hypertriglyceridemia Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Severe Hypertriglyceridemia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Severe Hypertriglyceridemia pipeline domain.

Key Takeaways from the Severe Hypertriglyceridemia Pipeline Report

  • Over 10+ Severe Hypertriglyceridemia pipeline therapies are in various stages of development, and their anticipated acceptance in the Severe Hypertriglyceridemia market would significantly increase market revenue. 
  • Leading Severe Hypertriglyceridemia companies developing novel drug candidates to improve the Severe Hypertriglyceridemia treatment landscape include Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, and others.
  • Promising Severe Hypertriglyceridemia pipeline therapies in various stages of development include ARO-APOC3, Olezarsen, and others.

Severe Hypertriglyceridemia Overview

Hypertriglyceridemia is a common condition, which is defined as having a high level (above 150 mg/dL) of triglycerides, a type of fat, in the bloodstream. Hypertriglyceridemia can lead to conditions including atherosclerosis (hardening of the arteries), obesity, and insulin resistance, which all can contribute to increased risk of cardiovascular disease (CVD). More than 2.1 million adults in the United States have severe hypertriglyceridemia (SHTG), defined as having a triglyceride level over 500 mg/dL. In addition to increasing the risk of CVD, SHTG is also a known risk factor for acute pancreatitis, a life-threatening condition. Risk factors for SHTG can include genetic disorders, obesity, untreated diabetes, and certain medications. While SHTG often causes no noticeable symptoms, individuals with extremely high levels of triglycerides (greater than 2,000 mg/dL) can experience recurrent abdominal pain, nausea, vomiting, xanthomas (yellow-colored bumps on the skin), and acute pancreatitis. There are many ways to prevent and treat SHTG. Lifestyle changes impacting SHTG include lowering fat and carbohydrate intake, reducing alcohol consumption, and quitting smoking. For some people, lifestyle changes aren’t enough to reduce triglycerides to the appropriate levels, leaving them at risk for additional complications. In these cases, there are pharmacological therapies that can reduce triglyceride levels to healthier levels

Severe Hypertriglyceridemia Pipeline Analysis: Drug Profile

ARO-APOC3: Arrowhead Pharmaceuticals

ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. Currently, it is in Phase II stage of clinical trial evaluation to treat Severe Hypertriglyceridemia.

Discover more about the emerging Severe Hypertriglyceridemia drugs @ Severe Hypertriglyceridemia Treatment Drugs

Severe Hypertriglyceridemia Key Companies

  • Arrowhead Pharmaceuticals
  • Ionis Pharmaceuticals

Severe Hypertriglyceridemia Pipeline Therapies

  • ARO-APOC3
  • Olezarsen

Severe Hypertriglyceridemia Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Severe Hypertriglyceridemia Pipeline Report 

  • Coverage: Global 
  • Key Severe Hypertriglyceridemia Companies: Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, and others
  • Key Severe Hypertriglyceridemia Pipeline Therapies: ARO-APOC3, Olezarsen, and others

Find out more about the Severe Hypertriglyceridemia treatment options in development @ Severe Hypertriglyceridemia Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the Severe Hypertriglyceridemia pipeline domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/